The ophthalmic drugs contract manufacturing market is estimated to be worth $0.79 billion in 2020 and is expected to grow at CAGR of 8% during the forecast period. According to the World Health Organization

The regulatory affairs management for medical devices market, valued at USD 594 billion in 2025, is projected to reach USD 633 billion in 2026 and USD 819 billion by 2030, with a 6.7% CAGR during the forecast period 2026 to 2030. According to the World Bank, more than 50,000 different types of medical devices are currently being used on a daily basis in healthcare facilities across the globe. Moreover, in 2018, the USFDA approved over 130 medical devices. However, a relatively large proportion...

The vaccine delivery devices market is estimated to be worth $1.5 billion by 2030, driven by the increase in global vaccination coverage. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%. Moreover, recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. As a result, significant efforts have been put into the development of drug delivery technologies / devices, s...

The global PARP inhibitors market is estimated to grow from USD 7.5 billion in 2024 to reach USD 8.5 billion in 2025 and USD 23.6 billion by 2035, representing a higher CAGR of 10.8% during the forecast period. Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality. Further, several such PARP inhibitors drugs are being investigated for the treatment of a myriad of advanced o...

Natural killer (NK) cells, or killer (K) cells, represent an important subset of cellular mediators of the innate immune system. Technically, they are classified as group I innate lymphocytes. Additionally, studies have demonstrated that NK cells can also secrete certain cytokines and chemokines, such as IFN? and TNF?, through which they can recruit other immune components to augment and sustain an immune response. Currently, these cells are being evaluated across multiple clinical trials to tr...

The global neoantigen targeted therapies market, valued at USD 661 million in 2025, is projected to reach USD 807 million in 2026 and USD 2,913 billion by 2030, with a 38% CAGR during the forecast period 2026 to 2030. Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The WHO has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Notably, amongst the targeted ant...

The clinical trial services market is estimated to be worth $9 billion in 2050 and is expected to grow at CAGR of over 14.1% during the forecast period. Estimates suggest that nearly 85% of clinical trials fail to retain enough patients for successful study conduct. Patient recruitment and retention-related concerns have been associated with massive delays, with over 90% of clinical trials failing to comply to predetermined completion dates. Such delays are estimated to result in capital losses...

Depression is a chronic medical condition characterized by a persistent feeling of sadness and lack of interest in external stimuli. It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide. Further, depression and other depressive disorders are projected to be responsible for an economic burden of up to USD 210 billion per year in the US. Despite the high prevalence and significant impact of this disease, less than 50% of affected individu...

The companion diagnostics market revenue is estimated to be reach $6 billion by 2030, driven by the companion diagnostics for oncology market segment. Over the years, many cases have been identified where conventional treatment options have failed to demonstrate any therapeutic benefit. It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. Further, a study of nearly 200 unique pharmacological interventions, across 670 clinical trials, concluded...

The global metabolic and cardiology stem cells market is likely to grow to USD 3.3 billion by 2030, driven by the rising prevalence of metabolic and cardiovascular disorders, increasing adoption of regenerative medicine approaches, and continued advancements in stem cell-based therapies.

The blockchain in genomic data management market, valued at USD 294.5 million in 2024, is projected to grow to USD 524.2 million in 2025 and USD 19,831.6 million by 2035, representing a CAGR of 43.8% during the forecast period. Blockchain technology has emerged as a viable option to store / exchange genomic data. The decentralized information management model used in blockchains has demonstrated significant benefits in banking and the fintech industry. Moreover, cryptocurrencies, which are based...

The extractable and leachable testing market is estimated to be worth $1 billion in 2028, growing at CAGR of 9.9 % during the forecast period. Notably, in 2010, McNeil Consumer Healthcare was compelled to recall more than 500 lots of Tylenol, Motrin, Benadryl and Zyrtec upon being made aware of the presence of an antifungal chemical, called 2, 4, 6-tribromoanisole (which is used to chemically treat shipping pallets), in the aforementioned product formulations. It is worth highlighting that this...

The global chronic pain treatment market, valued at USD 78.0 billion in 2024, is projected to reach USD 83.4 billion in 2025 and USD 155.2 billion by 2035, representing a CAGR of 6.4% during the forecast period. Additionally, there are various pain management devices that have been reported to significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly being used to treat a variety of clinical conditions that are characterized by chronic pain and o...

Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems.

The pharmaceutical spray drying market, valued at USD 2.2 billion in 2024, is projected to grow to USD 2.4 billion in 2025 and USD 5.0 billion by 2035, representing a CAGR of 7.6% during the forecast period. Spray drying, which is already established in the food and chemical sector, is also considered to be a rapid, cost-effective, and scalable process for the production of dry powder formulations of pharmacological material. Owing to characteristics, such as reproducibility and its continuous m...

The respiratory disorders market is estimated to be worth $5 billion in 2018 and is expected to grow at compounded annual growth rate (CAGR) of 14.7% during the forecast period. According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these death...

The global healthcare cybersecurity market size is estimated to reach $12.6 billion by 2030, growing at CAGR of 14% during the forecast period. Digitally stored information is prone to hacking and manipulation by cyber criminals. The concern is validated by the fact that more than 5.1 million records are compromised due to data breaches every day. In 2016, close to 1,800 incidents of data breaches were reported across all the industries; in total, almost 1.4 billion data records were lost or sto...

TThe global Back of The Eye Disorders Drugs and Technologies Market is expected to be worth $22.9 billion by 2030. According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be o...

The cancer stem cell therapies market, valued at USD 2.8 billion in 2024, is projected to grow to USD 3.1 billion in 2025 and USD 8.0 billion by 2035, representing a CAGR of 10.0% during the forecast period. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation of these cells. Presently, a number of initiatives are underway to explore specific targets that can be used to selectively eliminate cancer stem...

The global non-antibody protein scaffolds drugs / diagnostics market is expected to be worth $6.2 billion by 2030, representing a CAGR of of 42% during the forecast period. Although the concept of non-antibody protein scaffolds was conceived more than a decade ago, this field has gained popularity in recent years. The first product candidate was launched in 1986; since then, they have been used for the treatment of a myriad of diseases, including cancer, inflammatory diseases and infectious dise...